ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health. In addition, the company provides contract manufacturing services of OTC healthcare and dietary supplements products. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone215-345-0919
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.87 million
Profitability
Miscellaneous
Employees46
OptionableNot Optionable
ProPhase Labs (NASDAQ:PRPH) Frequently Asked Questions
What is ProPhase Labs' stock symbol?
ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."
How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs?
ProPhase Labs announced a special dividend on Thursday, December 27th. Shareholders of record on Thursday, January 10th will be given a dividend of $0.25 per share on Thursday, January 24th. The ex-dividend date of this dividend is Wednesday, January 9th. View ProPhase Labs' Dividend History.
How will ProPhase Labs' stock buyback program work?
ProPhase Labs declared that its board has initiated a stock repurchase plan on Saturday, November 11th 2017, which allows the company to buyback 1,700,000 outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through a tender offer. Stock buyback plans are generally an indication that the company's management believes its shares are undervalued.
How were ProPhase Labs' earnings last quarter?
ProPhase Labs Inc (NASDAQ:PRPH) posted its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $2.44 million for the quarter. ProPhase Labs had a negative net margin of 11.41% and a negative return on equity of 4.87%. View ProPhase Labs' Earnings History.
When is ProPhase Labs' next earnings date?
Has ProPhase Labs been receiving favorable news coverage?
News headlines about PRPH stock have trended positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ProPhase Labs earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Who are some of ProPhase Labs' key competitors?
Some companies that are related to ProPhase Labs include Ardelyx (ARDX), Spero Therapeutics (SPRO), Chimerix (CMRX), Adamis Pharmaceuticals (ADMP), Galmed Pharmaceuticals (GLMD), Imprimis Pharmaceuticals (IMMY), OASMIA PHARMACE/ADR (OASM), Marinus Pharmaceuticals (MRNS), Menlo Therapeutics (MNLO), Unum Therapeutics (UMRX), Processa Pharmaceuticals (PCSA), Axovant Sciences (AXON), BELLUS Health (BLUSF), Checkpoint Therapeutics (CKPT) and Northwest Biotherapeutics (NWBO).
Who are ProPhase Labs' key executives?
ProPhase Labs' management team includes the folowing people:
- Mr. Ted William Karkus, Chairman, CEO & Director (Age 60)
- Ms. Monica Brady, Chief Accounting Officer (Age 42)
How do I buy shares of ProPhase Labs?
Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProPhase Labs' stock price today?
One share of PRPH stock can currently be purchased for approximately $3.0050.
How big of a company is ProPhase Labs?
ProPhase Labs has a market capitalization of $34.71 million and generates $9.87 million in revenue each year. ProPhase Labs employs 46 workers across the globe.
What is ProPhase Labs' official website?
How can I contact ProPhase Labs?
ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company can be reached via phone at 215-345-0919 or via email at [email protected]
MarketBeat Community Rating for ProPhase Labs (NASDAQ PRPH)
MarketBeat's community ratings are surveys of what our community members think about ProPhase Labs and other stocks. Vote "Outperform" if you believe PRPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
